JP2019504064A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504064A5 JP2019504064A5 JP2018535391A JP2018535391A JP2019504064A5 JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5 JP 2018535391 A JP2018535391 A JP 2018535391A JP 2018535391 A JP2018535391 A JP 2018535391A JP 2019504064 A5 JP2019504064 A5 JP 2019504064A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 124
- 239000000203 mixture Substances 0.000 claims 65
- 239000000427 antigen Substances 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 18
- 210000003205 muscle Anatomy 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 208000020431 spinal cord injury Diseases 0.000 claims 11
- 102000004472 Myostatin Human genes 0.000 claims 10
- 108010056852 Myostatin Proteins 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 9
- 201000000585 muscular atrophy Diseases 0.000 claims 5
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 5
- 210000000577 adipose tissue Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000008595 infiltration Effects 0.000 claims 3
- 238000001764 infiltration Methods 0.000 claims 3
- 238000007918 intramuscular administration Methods 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 210000002161 motor neuron Anatomy 0.000 claims 3
- 206010002261 Androgen deficiency Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010068836 Metabolic myopathy Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 210000000593 adipose tissue white Anatomy 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004190 glucose uptake Effects 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 210000005228 liver tissue Anatomy 0.000 claims 2
- 230000037323 metabolic rate Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000005996 muscular dysfunction Effects 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 210000003486 adipose tissue brown Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000002638 denervation Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000002641 glycemic effect Effects 0.000 claims 1
- 230000002806 hypometabolic effect Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000001596 intra-abdominal fat Anatomy 0.000 claims 1
- 230000013190 lipid storage Effects 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 230000010120 metabolic dysregulation Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000007372 neural signaling Effects 0.000 claims 1
- 238000011859 neuroprotective therapy Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000009168 stem cell therapy Methods 0.000 claims 1
- 238000009580 stem-cell therapy Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022185469A JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276698P | 2016-01-08 | 2016-01-08 | |
| US62/276,698 | 2016-01-08 | ||
| US201662328597P | 2016-04-27 | 2016-04-27 | |
| US62/328,597 | 2016-04-27 | ||
| US201662333810P | 2016-05-09 | 2016-05-09 | |
| US201662333816P | 2016-05-09 | 2016-05-09 | |
| US62/333,810 | 2016-05-09 | ||
| US62/333,816 | 2016-05-09 | ||
| USPCT/US2016/052014 | 2016-09-15 | ||
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
| US201662413278P | 2016-10-26 | 2016-10-26 | |
| US62/413,278 | 2016-10-26 | ||
| PCT/US2017/012606 WO2017120523A2 (en) | 2016-01-08 | 2017-01-06 | Anti-pro/latent myostatin antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022185469A Division JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504064A JP2019504064A (ja) | 2019-02-14 |
| JP2019504064A5 true JP2019504064A5 (enExample) | 2020-03-12 |
Family
ID=59274466
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535391A Pending JP2019504064A (ja) | 2016-01-08 | 2017-01-06 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2022185469A Active JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A Pending JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022185469A Active JP7723649B2 (ja) | 2016-01-08 | 2022-11-21 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| JP2025128180A Pending JP2025170265A (ja) | 2016-01-08 | 2025-07-31 | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US10287345B2 (enExample) |
| EP (1) | EP3400240A2 (enExample) |
| JP (3) | JP2019504064A (enExample) |
| KR (1) | KR20180094110A (enExample) |
| CN (2) | CN115814077A (enExample) |
| AU (2) | AU2017206069A1 (enExample) |
| MX (3) | MX2018008369A (enExample) |
| SG (1) | SG11201805709RA (enExample) |
| WO (1) | WO2017120523A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| EP3056513A1 (en) | 2008-04-11 | 2016-08-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI761912B (zh) | 2010-11-30 | 2022-04-21 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| EP3721900A1 (en) | 2012-08-24 | 2020-10-14 | Chugai Seiyaku Kabushiki Kaisha | Fcgammariib-specific fc region variant |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI636062B (zh) | 2013-04-02 | 2018-09-21 | 中外製藥股份有限公司 | Fc region variant |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法 |
| CN112142844B (zh) | 2015-02-05 | 2025-07-25 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| IL305148A (en) | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE |
| MX2018008369A (es) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. |
| RS61090B1 (sr) | 2016-06-13 | 2020-12-31 | Scholar Rock Inc | Upotreba inhibitora miostatina i kombinovane terapije |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
| US12303498B2 (en) * | 2018-03-23 | 2025-05-20 | Cytoo | ALK5 inhibitors as skeletal muscle hypertrophy inducers |
| EP3807288A1 (en) | 2018-05-24 | 2021-04-21 | Valkyrie Pharmaceutics, Inc. | Methods and formulations for the treatment of obesity and obesity-related metabolic diseases |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| US11455381B2 (en) | 2020-04-21 | 2022-09-27 | CIELO Enterprise Solutions, Inc. | Systems and methods for providing multiple functionalities associated with a QR code |
| WO2022271867A1 (en) | 2021-06-23 | 2022-12-29 | Scholar Rock, Inc. | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| EP4426306A1 (en) * | 2021-10-06 | 2024-09-11 | F. Hoffmann-La Roche AG | Novel combined administration |
| AU2023413166A1 (en) | 2022-12-22 | 2025-07-03 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
Family Cites Families (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US5827733A (en) * | 1993-03-19 | 1998-10-27 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 (GDF-8) and polynucleotides encoding same |
| US7566768B1 (en) * | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| EP1574577A3 (en) | 1994-07-08 | 2006-06-14 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-11 |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO2000053211A2 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| MXPA02007295A (es) | 2000-01-28 | 2002-11-29 | Novo Nordisk As | Derivados de acido propionico alquinilsubstituidos y su uso contra diabetes y obesidad. |
| MXPA02012434A (es) | 2000-06-16 | 2004-09-06 | Cambridge Antibody Tech | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| ES2288900T3 (es) | 2001-10-05 | 2008-02-01 | Affimed Therapeutics Ag | Anticuerpo de origen humano para inhibir la agregacion de trombocitos. |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| US20070202104A1 (en) | 2002-07-19 | 2007-08-30 | Abbott Laboratories S.A. | Treatment of spondyloarthropathies using TNFalpha inhibitors |
| JP2006507356A (ja) | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
| SI1581649T1 (sl) | 2002-12-20 | 2011-09-30 | Amgen Inc | Vezna sredstva, ki zavirajo miostatin |
| US7371726B2 (en) | 2003-12-31 | 2008-05-13 | Schering-Plough Animal Health Corporation | Neutralizing GDF8 epitope-based growth enhancing vaccine |
| JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Ａｌｋ７およびミオスタチン阻害剤ならびにその使用 |
| ES2384176T3 (es) | 2004-03-23 | 2012-07-02 | Eli Lilly & Company | Anticuerpos anti-miostatina |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20100183695A1 (en) | 2004-05-27 | 2010-07-22 | John Knopf | Cerberus/coco derivatives and uses thereof |
| CA2575791A1 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| CA2590164A1 (en) | 2005-01-26 | 2006-08-03 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| AU2006239860B2 (en) | 2005-04-25 | 2012-01-19 | Amgen Fremont Inc. | Antibodies to myostatin |
| ES2534760T3 (es) * | 2005-08-19 | 2015-04-28 | Wyeth Llc | Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8 |
| EP1951756B1 (en) | 2005-10-06 | 2015-01-07 | Eli Lilly And Company | Anti-myostatin antibodies |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| CA2693378C (en) | 2006-08-03 | 2020-04-14 | Orico Limited | Myostatin antagonists |
| US8063188B2 (en) | 2006-09-05 | 2011-11-22 | Eli Lilly And Company | Anti-myostatin antibodies |
| US8895309B2 (en) | 2006-11-29 | 2014-11-25 | Nationwide Children's Hospital | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
| ATE542876T1 (de) | 2007-03-30 | 2012-02-15 | Merck Patent Gmbh | Doppelbrechungsschicht mit negativer optischer dispersion |
| JP2010529024A (ja) | 2007-06-01 | 2010-08-26 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｃｒｉｐｔｏ結合分子 |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| US8952130B2 (en) | 2009-02-24 | 2015-02-10 | The Salk Institute For Biological Studies | Designer ligands of TGF-β superfamily |
| EA201650137A1 (ru) | 2009-04-27 | 2017-09-29 | Новартис Аг | Композиции и способы для усиления мышечного роста |
| MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| US8945511B2 (en) | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
| EP2483300A4 (en) | 2009-10-01 | 2013-02-27 | Covita Ltd | SYNTHETIC PEPTIDE ANTAGONISTS OF MYOSTATIN |
| EP2545077B1 (en) | 2010-03-10 | 2018-10-31 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| TW201210612A (en) | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
| PE20131340A1 (es) | 2010-08-16 | 2013-11-29 | Amgen Inc | Polipeptidos que enlazan miostatina, composiciones y metodos |
| WO2013071056A2 (en) | 2011-11-11 | 2013-05-16 | Duke University | Combination drug therapy for the treatment of solid tumors |
| PL2780368T3 (pl) | 2011-11-14 | 2018-06-29 | Regeneron Pharmaceuticals, Inc. | Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| US8992913B2 (en) | 2012-06-15 | 2015-03-31 | Pfizer Inc. | Antagonist antibodies against GDF-8 and uses therefor |
| JP2016500704A (ja) | 2012-11-06 | 2016-01-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 細胞シグナル伝達を変調するための組成物及び方法 |
| SI2981822T1 (sl) | 2013-05-06 | 2021-08-31 | Scholar Rock, Inc. | Sestavki in postopki za modulacijo rastnega dejavnika |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| AU2014346457A1 (en) * | 2013-11-11 | 2016-06-02 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
| WO2016073853A1 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| JP6227191B1 (ja) | 2014-12-19 | 2017-11-08 | 中外製薬株式会社 | 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法 |
| EP3283519A1 (en) | 2015-04-15 | 2018-02-21 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL305148A (en) | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
| MX2018008369A (es) | 2016-01-08 | 2019-05-15 | Scholar Rock Inc | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. |
| RS61090B1 (sr) | 2016-06-13 | 2020-12-31 | Scholar Rock Inc | Upotreba inhibitora miostatina i kombinovane terapije |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
-
2017
- 2017-01-06 MX MX2018008369A patent/MX2018008369A/es unknown
- 2017-01-06 KR KR1020187022432A patent/KR20180094110A/ko active Pending
- 2017-01-06 EP EP17701024.6A patent/EP3400240A2/en active Pending
- 2017-01-06 AU AU2017206069A patent/AU2017206069A1/en not_active Abandoned
- 2017-01-06 CN CN202211417149.0A patent/CN115814077A/zh active Pending
- 2017-01-06 JP JP2018535391A patent/JP2019504064A/ja active Pending
- 2017-01-06 US US15/400,825 patent/US10287345B2/en active Active
- 2017-01-06 WO PCT/US2017/012606 patent/WO2017120523A2/en not_active Ceased
- 2017-01-06 CN CN201780015496.1A patent/CN109071645A/zh active Pending
- 2017-01-06 SG SG11201805709RA patent/SG11201805709RA/en unknown
-
2018
- 2018-07-05 MX MX2024006565A patent/MX2024006565A/es unknown
- 2018-07-05 MX MX2024006564A patent/MX2024006564A/es unknown
-
2019
- 2019-03-21 US US16/360,142 patent/US10882904B2/en active Active
-
2020
- 2020-10-29 US US17/083,917 patent/US12006359B2/en active Active
-
2022
- 2022-11-21 JP JP2022185469A patent/JP7723649B2/ja active Active
-
2024
- 2024-04-25 US US18/646,693 patent/US20240391989A1/en active Pending
- 2024-06-19 AU AU2024204159A patent/AU2024204159A1/en active Pending
-
2025
- 2025-07-31 JP JP2025128180A patent/JP2025170265A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504064A5 (enExample) | ||
| Zhou et al. | Cytokine signaling in skeletal muscle wasting | |
| JP2018535948A5 (enExample) | ||
| CN106068125B (zh) | 治疗脂肪组织积聚的组合物和方法 | |
| JP2015506944A5 (enExample) | ||
| JP2016536332A5 (enExample) | ||
| JP2013165711A5 (enExample) | ||
| IL295230A (en) | Combination therapy with anti-cd73 antibodies | |
| WO2008050329A3 (en) | Novel sirnas and methods of use thereof | |
| JP2010520290A5 (enExample) | ||
| Hao et al. | Ghrelin alleviates early brain injury after subarachnoid hemorrhage via the PI3K/Akt signaling pathway | |
| US20220152177A1 (en) | Treatment of diseases related to igfb3 and its receptor | |
| FI3565592T3 (fi) | Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio | |
| US20250122274A1 (en) | Selective and potent inhibitory antibodies of myostatin activation | |
| US20130344081A1 (en) | Method of treating amyotrophic lateral sclerosis | |
| CA3028586A1 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| JP2008540456A (ja) | 血管疾患の治療 | |
| CN108431039B (zh) | 改进的p2x7受体结合剂和包含其的多肽 | |
| US12098129B2 (en) | Pharmaceutical composition for treating fibrosis | |
| WO2018130513A1 (en) | Use of cd47 antibodies | |
| TW201945026A (zh) | 結合erfe之抗體及使用方法 | |
| JP2017501182A5 (enExample) | ||
| Zhang et al. | Hydroxysafflor yellow A attenuates carbon tetrachloride-induced hepatic fibrosis in rats by inhibiting Erk5 signaling | |
| WO2023001305A1 (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| WO2023019232A1 (en) | Anti-il-36r antibodies for the treatment of a fibrotic condition |